Tissue localization of Cryptococcus neoformans glucuronoxylomannan in the presence and absence of specific antibody - Wikidata - awgldk - TriplyDB

Tissue localization of Cryptococcus neoformans glucuronoxylomannan in the presence and absence of specific antibody

Tissue localization of Cryptococcus neoformans glucuronoxylomannan in the presence and absence of specific antibody

http://www.wikidata.org/entity/Q39822906

about

Fungal cell gigantism during mammalian infection Cryptococcus neoformans resides in an acidic phagolysosome of human macrophages Direct inhibition of T-cell responses by the Cryptococcus capsular polysaccharide glucuronoxylomannan.Spleen deposition of Cryptococcus neoformans capsular glucuronoxylomannan in rodents occurs in red pulp macrophages and not marginal zone macrophages expressing the C-type lectin SIGN-R1 Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies.Phenotypic switching of Cryptococcus neoformans can produce variants that elicit increased intracranial pressure in a rat model of cryptococcal meningoencephalitis Specific antibody to Cryptococcus neoformans alters human leukocyte cytokine synthesis and promotes T-cell proliferation.Organ-dependent variation of capsule thickness in Cryptococcus neoformans during experimental murine infection Cryptococcus neoformans Galactoxylomannan contains an epitope(s) that is cross-reactive with Aspergillus Galactomannan Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis.Clearance and organ distribution of Mycobacterium tuberculosis lipoarabinomannan (LAM) in the presence and absence of LAM-binding immunoglobulin M.Intracellular crystal formation as a mechanism of cytotoxicity in murine pulmonary Cryptococcus neoformans infection Fc-dependent and Fc-independent opsonization of Cryptococcus neoformans by anticapsular monoclonal antibodies: importance of epitope specificity Effects of voriconazole on Cryptococcus neoformans.Antibody to Cryptococcus neoformans glucuronoxylomannan inhibits the release of capsular antigen Receptor-mediated clearance of Cryptococcus neoformans capsular polysaccharide in vivo Binding and internalization of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans, by murine peritoneal macrophages Variable efficacy of passive antibody administration against diverse Cryptococcus neoformans strains.Antibody immunity and invasive fungal infections Radial mass density, charge, and epitope distribution in the Cryptococcus neoformans capsule.Isolation and purification of antigenic components of Cryptococcus Monoclonal antibodies reactive with immunorecessive epitopes of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans In vivo fate and distribution of poly-gamma-D-glutamic acid, the capsular antigen from Bacillus anthracis.Macrophage uptake, intracellular localization, and degradation of poly-gamma-D-glutamic acid, the capsular antigen of Bacillus anthracis.Evolutionarily conserved recognition and innate immunity to fungal pathogens by the scavenger receptors SCARF1 and CD36 The capsule of the fungal pathogen Cryptococcus neoformans.Identification and characterization of Cryptococcus neoformans protein fractions that induce protective immune responses Glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans, inhibits the progression of group B streptococcal arthritis.Phenotypic switching in Cryptococcus neoformans results in changes in cellular morphology and glucuronoxylomannan structure.Phagocytic activity and monocyte chemotactic protein expression by pulmonary macrophages in persistent pulmonary cryptococcosis.Contribution of Candida albicans cell wall components to recognition by and escape from murine macrophages.Antigenic and biological characteristics of mutant strains of Cryptococcus neoformans lacking capsular O acetylation or xylosyl side chains.Commentary: Role of Sterylglucosidase 1 (Sgl1) on the pathogenicity of Cryptococcus neoformans: potential applications for vaccine development.A purified capsular polysaccharide markedly inhibits inflammatory response during endotoxic shock.Fungal pathogen recognition by scavenger receptors in nematodes and mammals.Specific antibody can prevent fungal biofilm formation and this effect correlates with protective efficacy.Fungal serotype-specific differences in bacterial-yeast interactions.

P2860

Q27314614-A83794F3-EB47-40CB-BC2D-6741FD1C066D Q28295002-98E062F5-B355-4476-859D-A756929FB01B Q33263249-347BD90A-4A19-4FA2-959A-98BCBA5263FF Q33687443-E77ABBBE-C142-40EB-9704-4BC0DDD11634 Q33693515-36C162CE-2C1E-40B4-92CC-5C6B95E99A48 Q33716133-7C62B325-5476-482D-9CB3-BF2BA5981204 Q33751838-8F16EE82-F69D-4C76-8166-447F32C13B69 Q33766953-E6108C1D-40DD-40D2-88FB-50C6DA7EE639 Q33856355-EE9D4326-6D65-4A1E-A7E1-C1AC50898322 Q33857658-4142A5D6-BEB7-4BB3-890A-450921FE62A0 Q34003094-D93BAC80-B3B1-41FE-A0AD-E272366062CD Q34007067-3453F289-F0F7-4498-86E7-028A9043EE65 Q34123230-82C9917B-D634-4BF1-9A82-1AE9AC7A7F7B Q34142180-F256D709-AE87-4996-A014-B0DE510743A1 Q34146715-C776E01E-0C16-41C1-ACA3-73FB485094AE Q34194721-C85379E9-0558-4CEF-BC77-BD4236FB339C Q34301177-9D908E38-1C45-4906-96B8-6E52BEE10C5A Q35434901-3C2977C9-FF82-447A-98BF-BB901063110F Q35447692-66DF19C4-8FB8-4227-A241-646A367744A6 Q35641032-A29A0DDC-4F64-4AF8-A264-69F13CAC1B1A Q35813386-E460B9CC-4E17-4535-A5CF-B5C9DF045FD4 Q35923662-4372C7B7-2F60-42ED-867F-BF40D924254F Q36483647-97F1C6C2-E9B1-482D-BFD0-E5D01C93AF89 Q37032981-C2F72D48-4C4A-416C-A6F0-3572BDE74116 Q37234285-6F5BEBC1-DE20-4CC2-A37F-1A9CF2353CCC Q37337879-6E9C7CDD-A348-4D00-8560-AB9303F760F1 Q37562226-9F3025A1-76D4-48F6-9185-1D8144C83636 Q37582905-3D8F961C-B829-410A-8877-57F274747891 Q39512897-3BA440ED-CD3A-4478-BB58-8318847401E0 Q39714422-B4E566DA-DF68-4266-A588-202BEAB75909 Q39745251-ECAE5EAB-FD21-476A-8785-73CC554BDF75 Q39746326-BBADA5ED-CD8B-459C-B09C-4D94D8095CCD Q41069532-8D3AAC27-F333-4DAF-A131-1BA29F59DA13 Q42530714-EE2807F7-A283-481A-A003-286DD5678C4E Q42720029-53E85F57-C9EA-4865-A434-9B31F0323AB2 Q43013288-03FACE27-0C54-4B1D-AC31-364CDCD309F7 Q43077769-D0E450E0-9EDF-429F-BC6A-AF2879AB4AD1

P2860

Tissue localization of Cryptococcus neoformans glucuronoxylomannan in the presence and absence of specific antibody

http://www.wikidata.org/entity/Q39822906

description

1995 nî lūn-bûn

@nan

1995年の論文

@ja

1995年学术文章

@wuu

1995年学术文章

@zh-cn

1995年学术文章

@zh-hans

1995年学术文章

@zh-my

1995年学术文章

@zh-sg

1995年學術文章

@yue

1995年學術文章

@zh

1995年學術文章

@zh-hant

name

Tissue localization of Cryptoc ...... d absence of specific antibody

@en

Tissue localization of Cryptoc ...... absence of specific antibody.

@nl

type

label

Tissue localization of Cryptoc ...... d absence of specific antibody

@en

Tissue localization of Cryptoc ...... absence of specific antibody.

@nl

prefLabel

Tissue localization of Cryptoc ...... d absence of specific antibody

@en

Tissue localization of Cryptoc ...... absence of specific antibody.

@nl

P1433

Q39822906-9C24FCC4-8DD7-459D-83EA-E1F5F5D74D99

P1476

Q39822906-514A4DE8-F3D1-4C33-8E4C-27986FF98BEB

P2093

Q39822906-49503723-6B6E-49D5-A2CF-A414779742E7

Q39822906-7357E697-5537-4D9A-81AC-81F03446D53B

Q39822906-86A062D6-62A4-48C4-B787-6FFF7FB4FF43

P2860

Q39822906-2373D73D-69BD-4AD9-A0AD-168EA872A88C

Q39822906-2DF55FB8-CDD0-49C3-B156-2DBADD2EB695

Q39822906-2FEF40DE-7045-49A4-ABE9-0A233C2CF52B

Q39822906-306D553D-5C95-409A-9EFB-13CCAA2FF78B

Q39822906-32594710-9EA2-4005-BBA1-0EED672665B5

Q39822906-35C46019-A734-43F1-B27A-4DD82C3C266C

Q39822906-386FE665-04F8-4B4A-BD50-A4F31C47D5F9

Q39822906-3A60DE5D-C59A-447E-9247-1814AF1CD7F1

Q39822906-3ACE5BC0-CCB2-4BFC-A99E-88D2C6BCF314

Q39822906-3DE93B9E-8A7A-410C-A03D-8823E5BDBC91

P304

Q39822906-0D4CC298-C3F8-47FC-868A-BE0728893645

P31

Q39822906-5AD03F61-AADA-46E4-B95A-624F9C977EA0

P407

Q39822906-7B07A897-18A0-491B-AB1B-D4BCAB3D0F1E

P433

Q39822906-8327D5B7-E63A-4529-97EC-F42B6363A046

P478

Q39822906-8EE74CC6-4828-467F-B3BD-FFF93B9405E6

P577

Q39822906-2C4BF038-2957-4F8B-B069-C27A7870F50B

P698

Q39822906-C6F40CC2-6C13-419D-B54E-5605497A0518

P921

Q39822906-DA9DF305-9304-4EC0-82E6-9BFA1BEE1584

P932

Q39822906-816308D5-6B3F-46B6-BB9E-6B1825D44ACC

P1433

Infection and Immunity

P1476

Tissue localization of Cryptoc ...... d absence of specific antibody

@en

P2093

A Casadevall

http://www.w3.org/2001/XMLSchema#string

D L Goldman

http://www.w3.org/2001/XMLSchema#string

S C Lee

http://www.w3.org/2001/XMLSchema#string

P2860

T-cell-dependent and T-cell-independent mechanisms of tolerance to glucuronoxylomannan of Cryptococcus neoformans serotype A.

Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B.

Immune response to Cryptococcus neoformans soluble polysaccharide: immunological unresponsiveness

Immunological unresponsiveness induced by cryptococcal capsular polysaccharide assayed by the hemolytic plaque technique

Pathogenesis of pulmonary Cryptococcus neoformans infection in the rat

Reaction of germinal centers in the T-cell-independent response to the bacterial polysaccharide alpha(1-->6)dextran.

Intravascular cryptococcal culture filtrate (CneF) and its major component, glucuronoxylomannan, are potent inhibitors of leukocyte accumulation.

Monoclonal antibodies to Cryptococcus neoformans capsular polysaccharide modify the course of intravenous infection in mice.

Therapy for cryptococcal meningitis in patients with AIDS.

The mouse antibody response to infection with Cryptococcus neoformans: VH and VL usage in polysaccharide binding antibodies.

P304

3448-3453

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

63

http://www.w3.org/2001/XMLSchema#string

P577

1995-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

7642276

http://www.w3.org/2001/XMLSchema#string

P921

P932

173475

http://www.w3.org/2001/XMLSchema#string